Pular para o conteúdo principal

User account menu

  • Entrar

Idiomas

  • English
  • Français
  • Português
  • Español
  • العربية
  • Pусский

Navegação principal

  • Sobre o ISSUP

    • Fundamentação do ISSUP
    • Associação
      • Como se tornar um membro
      • Código de Ética
      • Who is ISSUP for?
    • Notícias
    • Parceiros Internacionais
    • Governança
    • ISSUP Scientific Council
    • Friends of ISSUP (USA)
    • ISSUP Workshops
      • Bali 2025
      • Thessaloniki 2024
      • Buenos Aires 2023
      • Manila 2022
      • Abu Dhabi 2022
      • International Conference 2021 (Virtual)
      • Africa 2020 (Virtual)
      • Viena 2019
      • Nairobi 2018
      • Cancún 2017
      • ISSUP Campinas 2016
      • ISSUP Tailandia 2015
    • Prémio ISSUP
      • Prémio Baseado em Evidências
      • Prémio de Iniciativa Local
      • Prémio de Serviços
      • Excellence in Training Provision
      • Outstanding Contribution to ISSUP Award
    • In Memoriam
    • Acknowledgements
    • Guias do site da ISSUP
    • Contate o ISSUP
    • FAQs - Frequently Asked Questions
  • Treinamento

    • Online Learning Hub
      • How to Register
      • UTC Self Led Courses
    • Universal Curricula (UC)
      • Currículo de Prevenção Universal
      • Currículo de Tratamento Universal
      • Universal Recovery Curriculum
      • Aceder UPC & UTC
      • Provedores de Formação
      • Tornar-se um Provedor de Formação
      • Programa Global de Formação
    • Resources
      • Glossary
      • ISSUP Webinars
      • ICAP certification
      • INEP Plus
      • Prevention Insights Video Series
      • Prevention Lists
      • HealthEKnowledge
      • WiRED International
      • Quality in Treatment
      • Manual de Investigação em Prevenção SPR-ISSUP
    • Job Board
  • Knowledge Share

    • Search in the Knowledge Share
    • ADDICTOLOGY Journal
      • Latest Issue
  • Comitês Nacionais

    • Africa
      • ISSUP Botswana
      • ISSUP Côte d’Ivoire
      • ISSUP Egypt
      • ISSUP The Gambia
      • ISSUP Kenya
      • ISSUP Namibia
      • ISSUP Nigeria
      • ISSUP South Africa
      • ISSUP Tanzania
      • ISSUP Togo
      • ISSUP Uganda
    • The Americas
      • ISSUP Argentina
      • ISSUP The Bahamas
      • ISSUP Brazil
      • ISSUP Canada
      • ISSUP Chile
      • ISSUP Colombia
      • ISSUP Ecuador
      • ISSUP El Salvador
      • ISSUP Guatemala
      • ISSUP Mexico
      • ISSUP Panama
      • ISSUP Paraguay
      • ISSUP Peru
      • ISSUP United States
    • Asia
      • ISSUP Afghanistan
      • ISSUP India
      • ISSUP Indonesia
      • ISSUP Kazakhstan
      • ISSUP Lebanon
      • ISSUP Malaysia
      • ISSUP in Pakistan
      • ISSUP Philippines
      • ISSUP Qatar
      • ISSUP Sri Lanka
      • ISSUP Thailand
      • ISSUP Türkiye
      • ISSUP United Arab Emirates
      • ISSUP Uzbekistan
      • ISSUP Vietnam
    • Europe
      • ISSUP Czech Republic
      • ISSUP Greece
      • ISSUP Italy
      • ISSUP Spain
      • ISSUP Ukraine
      • ISSUP United Kingdom
    • How to Become a National Chapter
    • ISSUP National Chapters' Advisory Committee
  • Events

    • Search through all events
  • Fórum

    • A–Z
  • My ISSUP

    • Member Directory
    • Candidate-se para adesão

Opioids

Network for information about opioids
DiscussionsArquivosImagensVideosLinksEventosKnowledge ShareTudo
Jose Luis Vazquez Martinez

Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

Jose Luis Vazquez Martinez - 9 May 2025
Source: Onuoha, E. N., Leff, J. A., Schackman, B. R., McCollister, K. E., Polsky, D., & Murphy, S. M. (2021). Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value in Health, 24(7), 1068-1083. Highlights •There is new evidence on buprenorphine...
Click here → to read the full text
  • Leia mais sobre Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
  • Comentar
Jose Luis Vazquez Martinez

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence A Systematic Review and Meta-analysis

Jose Luis Vazquez Martinez - 9 May 2025
Source: Santo T, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979–993. doi:10.1001/jamapsychiatry.2021.0976 Key Points...
Click here → to read the full text
  • Leia mais sobre Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence A Systematic Review and Meta-analysis
  • Comentar
Joanna

Approach and Management to Newborns with Prenatal Opioid Exposure

Shared by Joanna (ISSUP staff) - 7 May 2025
Event Date
9 de Maio de 2025
Location:
Online
Estados Unidos

On May 9th | 🕛 12 PM EST (Washington DC time) Find your local time zone using the https://dateful.com/time-zone-converter

Join Dr. Alison Sweeney of UNC Chapel Hill for an insightful session on:


👶 Recognizing signs and symptoms of opioid...

  • Leia mais sobre Approach and Management to Newborns with Prenatal Opioid Exposure
  • Comentar
James Harvey

Approach and Management to Newborns with Prenatal Opioid Exposure

Shared by James Harvey (ISSUP staff) - 6 May 2025
Approach and Management to Newborns with Prenatal Opioid Exposure
Event Date
9 de Maio de 2025
Location:
Washington DC
Estados Unidos
Join Dr. Alison Sweeney of UNC Chapel Hill for an insightful session covering how to recognise signs and symptoms of opioid exposure in infants. The webinar will discuss treatment strategies (including Eat, Sleep, Console) and team-based care to support families.
  • Leia mais sobre Approach and Management to Newborns with Prenatal Opioid Exposure
  • Comentar
James Harvey

"Addressing Underlying Trauma in Opioid Use" with speaker Tanya Saraiya, PhD

Shared by James Harvey (ISSUP staff) - 21 April 2025
Event Date
22 de Abril de 2025
Location:
Washington, DC
Estados Unidos

Trauma exposure and the subsequent development of post-traumatic stress symptoms (PTSS) or post-traumatic stress disorder (PTSD) frequently co-occur with opioid use disorder (OUD). The interaction between these elements yields complex...

  • Leia mais sobre "Addressing Underlying Trauma in Opioid Use" with speaker Tanya Saraiya, PhD
  • Comentar
Rasha Abi Hana

Effectiveness of nurse-initiated smoking cessation intervention: a systematic review and meta-analysis

Shared by Rasha Abi Hana - 14 April 2025
Format
Scientific article
Published by / Citation
Lee, EH., Yu, HJ. Effectiveness of nurse-initiated smoking cessation intervention: a systematic review and meta-analysis. Subst Abuse Treat Prev Policy 20, 18 (2025). https://doi.org/10.1186/s13011-025-00648-8

Background
Smoking is one of the top causes of preventable death and is linked to many serious health problems, including cancer and chronic diseases. Nurses can play a big role in helping people quit smoking by offering support through counselling, education, and mental health care. These nurse-led programs have been shown to increase quit rates. Training nurses to deliver these programs is important, and reviewing past studies helps us understand what works best.

Methods
Researchers searched eight major health databases between March 27 and August 1, 2024, to find studies on nurse-led...

  • Leia mais sobre Effectiveness of nurse-initiated smoking cessation intervention: a systematic review and meta-analysis
  • Comentar
Rasha Abi Hana

Canadian Substance Use Costs and Harms Online Data Visualisation Tool

Shared by Rasha Abi Hana - 2 April 2025
Format
Guide
Published by / Citation
Canadian Substance Use Costs and Harms (CSUCH)

CSUCH’s data visualisation tool can be used to estimate substance use trends across the country. The data helps inform programs, practices, and research to protect communities, save lives, and improve the well-being of people in Canada.

 

Spotlight: Top 3 causes of death due to substance use in Canada 


More than 200 people died each day due to substance use (SU) in 2020 (the latest year for which data are available). That works out to 73,994 deaths that year. The average age of death due to SU was 45 years. Tobacco use caused 63% (46,366) of SU-related deaths, followed by alcohol at 23%...

  • Leia mais sobre Canadian Substance Use Costs and Harms Online Data Visualisation Tool
  • Comentar
Rasha Abi Hana

Perceived impacts of North Americas first de-medicalised safer supply program

Shared by Rasha Abi Hana - 31 March 2025
Format
Scientific article
Published by / Citation
Kalicum, J., Nyx, E., Kennedy, M.C. et al. Perceived impacts of North Americas first de-medicalized safer supply program. Subst Abuse Treat Prev Policy 20, 11 (2025). https://doi.org/10.1186/s13011-025-00642-0

Background
A non-medicalized safer supply model called a “Compassion Club” has recently been evaluated. The model involved providing rigorously tested and accurately labeled illicit substances to members at cost. Operating for 14 months in Vancouver's Downtown Eastside, the initiative aimed to explore the effects and feasibility of this approach among individuals at risk of fatal overdose.

Methods
At the one-year mark, 43 club members completed a survey for this cross-sectional analysis. Descriptive statistics were used to assess the perceived impact of membership on factors like drug use...

  • Leia mais sobre Perceived impacts of North Americas first de-medicalised safer supply program
  • Comentar
Rasha Abi Hana

VCU researchers are developing a long-acting medication for opioid addiction

Shared by Rasha Abi Hana - 24 March 2025
Format
News
Published by / Citation
VCU

Researchers at Virginia Commonwealth University (VCU) have developed a new version of a medication for opioid use disorder that could offer longer-lasting treatment. Current medications for opioid addiction often require daily doses, but the new formulation of nor-levo-alpha-acetylmethadol (nor-LAAM) is designed to be taken once a month or less frequently. This long-acting medication has shown promise in reducing opioid use and withdrawal symptoms in rodent models. The goal is to provide an alternative to existing treatments like methadone and buprenorphine, which come with barriers such as...

  • Leia mais sobre VCU researchers are developing a long-acting medication for opioid addiction
  • Comentar
Rasha Abi Hana

Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder

Shared by Rasha Abi Hana - 14 March 2025
Format
Scientific article
Published by / Citation
Monico, L.B., Eastlick, M., Michero, D. et al. Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder. Subst Abuse Treat Prev Policy 20, 8 (2025). https://doi.org/10.1186/s13011-024-00631-9

Background
The opioid epidemic in the U.S. contributes to increased morbidity and mortality from drug overdoses, but barriers to traditional opioid use disorder (OUD) treatment limit access to care. During the COVID-19 pandemic, Public Health Emergency (PHE) provisions relaxed in-person requirements for buprenorphine inductions, expanding telehealth options for OUD treatment. This study explores patients' experiences with a digital therapeutic telehealth program offering buprenorphine for OUD.

Methods
Semi-structured qualitative interviews were conducted with 15 participants from a larger...

  • Leia mais sobre Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder
  • Comentar
Jose Luis Vazquez Martinez

USA Federal Drug Testing Program Adds Fentanyl Testing

Jose Luis Vazquez Martinez - 16 January 2025
Source: https://www.govinfo.gov/content/pkg/FR-2025-01-16/pdf/2025-00425.pdf The U.S. Department of Health and Human Services (HHS) added fentanyl to its drug testing protocol. The revised drug testing panels will go into effect on July 7, 2025.
USA Federal Drug Testing Program Adds Fentanyl Testing.pdf
  • Leia mais sobre USA Federal Drug Testing Program Adds Fentanyl Testing
  • Comentar
Jose Luis Vazquez Martinez

Frontal White Matter Changes and Craving Recovery in Inpatients With Heroin Use Disorder

Jose Luis Vazquez Martinez - 19 December 2024
Source: Gaudreault P, King SG, Huang Y, et al. Frontal White Matter Changes and Craving Recovery in Inpatients With Heroin Use Disorder. JAMA Netw Open. 2024;7(12):e2451678. doi:10.1001/jamanetworkopen.2024.51678 Key Points Question Does white matter microstructure change during medication-assisted...
Frontal White Matter Changes and Craving Recovery in Inpatients With Heroin Use Disorder.pdf
  • Leia mais sobre Frontal White Matter Changes and Craving Recovery in Inpatients With Heroin Use Disorder
  • Comentar
James Harvey

2025 NIDA International Forum Call for Research Poster Abstract Submissions and Travel Award Requests

Shared by James Harvey (ISSUP staff) - 18 December 2024
The NIDA International Program invites researchers from around the world to present their international drug use and addiction research during the 2025 NIDA International Forum.
Format
News
The NIDA International Program invites researchers from around the world to present their international drug use and addiction research during the 2025 NIDA International Forum.
  • Leia mais sobre 2025 NIDA International Forum Call for Research Poster Abstract Submissions and Travel Award Requests
  • Comentar
Jose Luis Vazquez Martinez

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis

Jose Luis Vazquez Martinez - 17 October 2024
Source: Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2024...
The association between glucose-dependent insulinotropic polypeptide and or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders.pdf
  • Leia mais sobre The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis
  • Comentar
James Harvey

The Overdose Crisis Across the Globe: An Expert Panel Discussion

Shared by James Harvey (ISSUP staff) - 3 September 2024
International Overdose Awareness Day 2024.
Format
Video and audio recordings
Published by / Citation
Penington Institute
This webinar hosted by the Penington Institute to Mark International Overdose Awareness Day 2024 brings together a panel with diverse perspectives, insights, experiences, research, and solutions to the overdose crisis.
  • Leia mais sobre The Overdose Crisis Across the Globe: An Expert Panel Discussion
  • Comentar
Jose Luis Vazquez Martinez

Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain: A systematic review and meta-analysis

Jose Luis Vazquez Martinez - 30 August 2024
Source: Thomas, K. H., Dalili, M. N., Cheng, H. Y., Dawson, S., Donnelly, N., Higgins, J. P., & Hickman, M. (2024). Prevalence of problematic pharmaceutical opioid use in patients with chronic non‐cancer pain: A systematic review and meta‐analysis. Addiction. Abstract Background and aims Chronic non...
Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain A systematic review and meta-analysis.pdf
  • Leia mais sobre Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain: A systematic review and meta-analysis
  • Comentar
Rasha Abi Hana

Opioid-Overdose Reduction Continuum of Care Approach (ORCCA) Practice Guide 2023

Shared by Rasha Abi Hana - 26 August 2024
SAMHSA
Format
Guide
Published by / Citation
SAMHSA

This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.

Traduções
Español
Pусский
Vietnamese
  • Leia mais sobre Opioid-Overdose Reduction Continuum of Care Approach (ORCCA) Practice Guide 2023
  • Comentar
Rasha Abi Hana

Overdose Prevention and Response Toolkit

Shared by Rasha Abi Hana - 26 August 2024
SAMHSA
Format
Toolkit
Published by / Citation
SAMHSA

SAMHSA’s updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential aspects of overdose prevention.

The toolkit, designed to augment overdose prevention and reversal training, provides guidance on the role of opioid overdose reversal medications, including naloxone and nalmefene, and how to respond to an overdose. It also contains appendices for specific audiences, including people who use drugs (PWUD), people who take...

  • Leia mais sobre Overdose Prevention and Response Toolkit
  • Comentar
James Harvey

UNODC World Drug Report 2024

Shared by James Harvey (ISSUP staff) - 1 July 2024
UNODC World Drug Report 2024
Format
Report
Published by / Citation
UNODC
A global reference on drug markets, trends and policy developments, the World Drug Report offers a wealth of data and analysis and in 2024 comprises several elements tailored to different audiences.
  • Leia mais sobre UNODC World Drug Report 2024
  • Comentar
Rasha Abi Hana

Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study

Shared by Rasha Abi Hana - 30 May 2024
Format
Scientific article
Published by / Citation
Druckrey-Fiskaaen, K.T., Vold, J.H., Madebo, T. et al. Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study. Subst Abuse Treat Prev Policy 19, 21 (2024). https://doi.org/10.1186/s13011-024-00603-z

Background:

People who have problems with using opioids or other drugs and inject them have shorter lives than most people. Liver diseases, especially, contribute to this. Checking liver stiffness might help find liver problems early. This study looks at how common liver disease is in people who use drugs and how different factors like types of drugs used, hepatitis C, alcohol, weight, age, diabetes, and cholesterol affect liver stiffness.

Methods:

From May 2017 to March 2022, data was collected from 676 people in Western Norway. Most were getting treatment for opioid addiction, while some...

  • Leia mais sobre Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
  • Comentar

Paginação

  • Página atual 1
  • Página 2
  • Página 3
  • Página 4
  • Página 5
  • Página 6
  • …
  • Próxima página ››
  • Última página Last »

Upcoming Events

There aren't any upcoming events
All Events
Contate-nos

Stay Connected

Newsletter

ISSUP is funded by the U.S. Department of State via the Bureau of International Narcotics and Law Enforcement Affairs (INL). INL works to keep Americans safe by countering crime, illegal drugs, and instability abroad.

Copyright © International Society of Substance Use Prevention and Treatment Professionals Privacy Policy